Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

NIAID awards Caprion a $12.9 million infectious disease biomarkers contract

Caprion Proteomics : 07 October, 2008  (Company News)
Caprion Proteomics has been awarded a $12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health, to carry out Biodefense research in the area of infectious disease biomarkers.
Under the contract to be performed over a five-year period, Caprion will act as one of two NIAID Clinical Proteomics Centers for Infectious Disease and Biodefense, and will employ its distinctive CellCarta quantitative protein profiling technologies to perform several large scale applied proteomics projects using human clinical samples from patients with infectious diseases.

The projects will be aimed at the discovery, qualification, and verification of candidate biomarkers with potential for clinical use to improve detection and diagnosis and to monitor therapeutic and vaccine responses and susceptibility to infection for diseases caused by various pathogens. This is the second major Biodefense research contract awarded to Caprion by NIAID builds on the expertise and results demonstrated by Caprion as part of an initial contract awarded in 2004 and still in progress.

'We are very pleased to be granted the opportunity to expand our infectious disease research programme with NIAID into the area of clinical Biomarker discovery and validation,' said Martin LeBlanc, president and chief executive officer at Caprion. 'This second major contract award from the NIAID provides further evidence of Caprion's solid scientific capabilities and industry leadership position as a proteomics and Biomarker services provider.'

Caprion will retain rights to commercialise candidate biomarkers and diagnostic products discovered in this project.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo